PharmaCyte Biotech Inc (OTC: PMCB) is an early-stage biotechnology company developing cell-based therapies for cancer and other diseases. The company generates no revenue, funding operations through capital markets rather than product sales. As of the 10-K filed August 11, 2025, PharmaCyte reported zero revenues for the fiscal years ended April 30, 2025 and April 30, 2024. Its primary clinical program targets locally advanced pancreatic cancer (LAPC), for which an Investigational New Drug (IND) application submitted to the FDA in September 2020 has been on clinical hold since October 2020. During the fiscal year ended April 30, 2025, the company's scientific consultants were in active dialog with the FDA seeking permission to forego a required large animal study. PharmaCyte has experienced significant management turnover, including changes to its Chief Executive Officer and Board, and describes itself as highly dependent on its CEO and CFO. The company operates with a limited number of employees and has long-lived assets located in multiple countries.

Revenue model

No revenue. The company is pre-commercial and generates no product sales, licensing fees, or royalties. Operations are funded through external financing. Zero revenues were reported for fiscal years ended April 30, 2025 and April 30, 2024.

Products and services

Primary pipeline candidate: a cell-based therapy for locally advanced pancreatic cancer (LAPC) using intra-arterial chemotherapy delivery. An IND for a planned LAPC clinical trial was submitted to the FDA in September 2020 and placed on clinical hold in October 2020. The company has been working to address FDA requirements to lift the hold, including seeking to forego a large animal study requirement as of fiscal year ended April 30, 2025.

Customers and end markets

No commercial customers. Target end market is oncology, specifically patients with locally advanced pancreatic cancer. The company is also pursuing orphan drug designations in the United States and European Union for rare or life-threatening conditions.

Value-chain role

Pre-commercial drug developer. The company conducts research and development, works with scientific and regulatory consultants, and engages with the FDA on clinical trial authorization. It does not manufacture, distribute, or sell any commercial products.

Geographic exposure

The company operates globally and is developing products in multiple countries. No revenues from domestic or foreign sources were reported for fiscal years ended April 30, 2025 or April 30, 2024. Long-lived assets are located in multiple geographical areas per the 10-K filed August 11, 2025.

Source: SEC 10-K, filed 2025-08-11

Industry: Biological Products, (No Diagnostic Substances) Peers: AquaBounty Technologies Inc Exagen Inc TYME TECHNOLOGIES, INC. Immunome Inc Lite Strategy Inc MERRIMACK PHARMACEUTICALS INC Sensei Biotherapeutics Inc Sera Prognostics Inc TScan Therapeutics Inc